Filing Flows › Maxcyte (MXCT) › Q1 2026 › vs Q1 2025
Maxcyte (MXCT) Q1 2026 vs Q1 2025 (year over year)
Maxcyte's revenue fell $739K (-7%) from $10.4M in Q1 2025 to $9.7M in Q1 2026. The biggest changes: Product sales −$1.7M (-32%); Licenses +$853K (+18%); Assay and other service revenue +$85K (+21%).
Maxcyte, Q1 2026: revenue $9.7M (-7% year over year), operating margin -64.1%, net loss $4.8M, operating cash flow −$8.2M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Licenses | $5.5M | $4.7M | $853K | +18% |
| Product sales | $3.6M | $5.3M | −$1.7M | -32% |
| Assay and other service revenue | $482K | $397K | $85K | +21% |
| Revenue | $9.7M | $10.4M | −$739K | -7% |
| Other income, net | $1.4M | $2.0M | −$599K | -29% |
| Net loss | $4.8M | $10.3M | −$5.5M | -54% |
| Costs & expenses | $15.8M | $22.7M | −$6.8M | -30% |
| Operating costs | $15.8M | $22.7M | −$6.8M | -30% |
| Cost of revenue | $1.6M | $1.5M | $72K | +5% |
| Research & development | $3.9M | $5.9M | −$2.0M | -35% |
| Sales & marketing | $3.4M | $5.7M | −$2.3M | -40% |
| General & admin | $6.0M | $8.5M | −$2.6M | -30% |
| Other operating costs | $1.0M | $1.1M | −$45K | -4% |
| Operating cash sources | $10.4M | $18.5M | −$8.2M | -44% |
| Depreciation & amortization | $1.0M | $1.1M | −$49K | -4% |
| Share-based compensation | $1.1M | $3.0M | −$1.9M | -62% |
| Cash used in operations | $8.2M | $14.4M | −$6.2M | -43% |
| Net loss absorbed | $4.8M | $10.3M | −$5.5M | -54% |
| Working capital & other | $5.6M | $8.3M | −$2.7M | -32% |
Questions
How much did Maxcyte's revenue grow year over year in Q1 2026?
Maxcyte's revenue fell $739K (-7%) from $10.4M in Q1 2025 to $9.7M in Q1 2026.
What drove Maxcyte's revenue change in Q1 2026?
Product sales −$1.7M (-32%); Licenses +$853K (+18%); Assay and other service revenue +$85K (+21%).